120202-69-9

Usage

Uses

Used in Pharmaceutical Industry:
Clopidogrel Impurity C is used as a reference standard for the analysis of clopidogrel, a medication used to prevent blood clots, ensuring the quality and purity of the final product.
Clopidogrel Impurity C is used for research and development purposes to study the pharmacological and toxicological properties of clopidogrel and its related compounds.
Clopidogrel Impurity C is used for quality control and regulatory compliance of clopidogrel products, as its characterization and quantification are essential in maintaining product standards.

Upstream product

• 35963-20-3 (R)-10-camphorsulfonic acid 
• 90055-48-4 clopidogrel 
• 67-56-1 methanol 
• 929200-24-8 sodium (R)-(2-chlorophenyl)-(6,7-dihydro-4H-thieno[3,2-c]pyridin-5-yl)-acetate 
• 77-78-1 dimethyl sulfate 
• 10421-85-9 (R)-2-chloromandelic acid 
• 28783-41-7 6,7-dihydro-4H-thieno[3,2-c]pyridine hydrochloride 
• 847986-65-6 (R)-(-)-camphorsulphonic scid salt of methyl (R)-(-)-α-(2-chlorophenyl)-6,7-dihydrothieno[3,2-c]pyridine-5(4H)-acetate 

Downstream Products

• 90055-48-4 clopidogrel 
• 120202-66-6 (S)-(+)-clopidogrel bisulfate 
• 929200-19-1 sodium (+/-)-(2-chlorophenyl)-(6,7-dihydro-4H-thieno[3,2-c]pyridin-5-yl)-acetate 
• 120202-71-3 methyl (S)-(+)-2-(2-chlorophenyl)-2-(6,7-dihydrothieno-[3,2-c]pyridin-5(4H)-yl)acetate bisulfate 
• 929200-21-5 (+/-)-(2-chlorophenyl)-(4,5,6,7-4H-thieno[3,2,-c]pyrid-5-yl) potassium acetate 

Relevant academic research and scientific papers

Method for recycling S - O-chloromandelic acid

The invention belongs to the technical field of chemical synthesis, and discloses a method for recycling S-o-chloromandelic acid. The o-chloromandelic acid is a clopidogrel hydrogen sulfate starting material. The method is characterized by comprising the following steps: concentrating a lipid solution of S-o-chloromandelic acid to dryness, and adding an alkaline aqueous solution to react at a hightemperature to racemize the S-o-chloromandelic acid; after the reaction is completed, adding a C2-C8 lipid solvent and adjusting the pH of the solution with an inorganic acid to be acidic; separatingan aqueous phase from an organic phase, and allowing the organic phase to be dried and directly reacted with a resolving agent to prepare R-o-chloromandelic acid. The invention provides a method forrecycling clopidogrel hydrogen sulfate intermediate waste, the influence of reaction byproducts on the environment is eliminated, the S-o-chloromandelic acid is converted and then used in the preparation process of clopidogrel hydrogen sulfate, and the economic value is very high.

PROCESS FOR THE PREPARATION OF CLOPIDOGREL POLYMORPHOUS FORM 1 USING SEED CHRYSTALS

The invention relates to the process for the preparation of hydrogen sulfate salt of dextro rotatory Methyl - α - 5 - (4,5,6,7- tetrahydro - (3,2-c ) thienopyridyl) - (2-chlorophenyl) acetate which is generally referred as clopidogrel hydrogen sulfate ( I

RACEMIZATION PROCESS FOR THE PREPARATION OF AN INTERMEDIATE OF CLOPIDOGREL HYDROGEN SULPHATE

The invention relates to a process for the preparation of the pharmaceutically applicable methyl (S)-(+)-α-(2-chlorophenyl)-6,7-dihydrothieno[3,2-c]pyridine-5(4H)- acetate hydrogen sulphate (also known as S-(+)-clopidogrel hydrogen sulphate) of formula (I) comprising racemizing methyl (R)-(-)-α-(2-chlorophenyl)-6,7-dihydrothieno[3,2-c]pyridine- 5(4H)-acetate or methyl (S)-(+)-α-(2-chlorophenyl)-6,7-dihydrothieno[3,2-c]pyridine-5(4H)- acetate, or a mixture thereof in any proportion with a weak base in the presence of an organic solvent, converting the methyl (R,S)-(±)-α-(2-chlorophenyl)-6,7-dihydrothieno [3,2-c]pyridine-5(4H)-acetate of fomula (II) obtained to its sulphuric acid addition salt methyl (R,S)-(±)-α-(2-chlorophenyl)-6,7-dihydrothieno[3,2-c]pyridine-5(4H)-acetate hydrogen sulphate and converting it to methyl (S)-(+)-α-(2-chlorophenyl)-6,7-dihydrothieno[3,2-c] pyridine-5(4H)-acetate hydrogen sulphate of formula (I) by known manner.

PROCESSES FOR THE PREPARATION OF CLOPIDOGREL

The invention relates to processes for the preparation of clopidogrel and salts thereof. The inventors have developed a process for preparing racemic clopidogrel by racemizing R(-) clopidogrel. The process includes the step of reacting R(-) clopidogrel with a powered anhydrous base in one or more solvents.

Procedure for the preparation of methyl (+)-(S)-Alpha-(O-chlorophenyl)-6,7-dihydrothieno-[3,2-C]pyridine-5(4H) acetate

A process for the preparation of Methyl (+)-(S)-α-(o-chlorophenyl)-6,7-dihydrothieno-[3,2-c]pyridine-5(4H)acetate of formula I: the process comprising: a. reacting 4,5,6,7-tetrahydro[3,2-c]thieno pyridyl methane (II) with 2-halophenyl acetic acid derivative of formula III b. extracting the formed product (+/-) clopidogrel in to solvent from the reaction mixture of step a; c. resolution of (+/-) clopidogrel of step b with levorotatory camphor sulfonic acid and isolation of the (+) clopidogrel camphor sulfonic acid salt; d. purifying (+) clopidogrel camphor salt; and e. neutralization of the camphor salt of step d with aqueous base in solvent and isolation of (+) clopidogrel base by separation and removal solvent.

PROCESS FOR PREPARING CLOPIDOGREL

A process for the preparation of clopidogrel of formula (I) or its pharmaceutically acceptable salts, solvates, hydrates thereof is disclosed. The process comprises treating (+)-(S)-2-Chlorophenyl-(6,7-dihydro-4H-thieno[3,2- c]pyridin-5-yl)acetamide of formula (II) with acid to provide novel acid salt of (+)-(S)- 2-Chlorophenyl-(6,7-dihydro-4H-thieno[3,2-c]pyridin-5-yl)acetamide of formula (III) wherein in S represent acid selected from hydrochloric acid, hydrobromic acid, phosphoric acid, benzoic acid, succinic acid, oxalic acid, malic acid, maleic acid, methanesulfonic acid, ethane sulfonic acid, benzenesulfonic acid, p-toluene sulfonic acid, nephthalene sulfonic acid and converting acid salt of (+)-(S)-2-Chlorophenyl- (6,7-dihydro-4H-thieno[3,2-c]pyridin-5-yl)acetamide to Clopidogrel (I) and its pharmaceutically acceptable salts, hydrates, solvates thereof.

PREPARATION OF CLOPIDOGREL AND ITS ANALOGUES METHYL TETRAHYDROTHIENOPYRIDINE ACETATE COMPOUNDS

The present invention disclosed a preparation method of Clopidogrel (X=2-Cl) and its analogues of methyl tetrahydrothienopyridine acetate (I) by using halogen phenyl acetonitrile (VIII) as starting material and tetrahydrothienopyridine acetonitrile (IV), tetrahydrothienopyridine acetate (V) as key intermediates, and further using kinetic resolution to prepare the optical active Clopidogrel and compounds of methyl tetrahydrothenopridine acetate of formula (XII). The Clopidogrel of present invention is a novel high effective and safety drug for inhibition of platelet aggregation. This invention applied systematic technique of racemization of unwanted optical active enantiomer, recover recycle and reuse of resolution agent etc., with greater economic advantages and suitable for commercial scale industrial production. Wherein: X represents atoms of hydrogen, fluorine, chlorine, bromine or iodine, M represents an alkali metal ion.

Preparation of Clopidogrel and Its Analogues Methyl Tetrahydrothienopyridine Acetate Compuunds

The present invention disclosed a preparation method of Clopidogrel (X=2-Cl) and its analogues of methyl tetrahydrothienopyridine acetate (I) by using halogen phenyl acetonitrile (VIII) as starting material and tetrahydrothienopyridine acetonitrile (IV), tetrahydrothienopyridine acetate (V) as key intermediates, and further using kinetic resolution to prepare the optical active Clopidogrel and compounds of methyl tetrahydrothenopridine acetate of formula (XII). The Clopidogrel of present invention is a novel high effective and safety drug for inhibition of platelet aggregation. This invention applied systematic technique of racemization of unwanted optical active enantiomer, recover recycle and reuse of resolution agent etc., with greater economic advantages and suitable for commercial scale industrial production. Wherein: X represents atoms of hydrogen, fluorine, chlorine, bromine or iodine, M represents an alkali metal ion.

A PROCESS FOR PREPARING (S)-(+)-CLOPIDOGREL BASE AND ITS SALTS

The present invention relates to an improved processes for the preparation of Methyl (+)-(S)-(2-chlorophenyl)-(6,7dihydro-4H-thieno[3,2-c]pyridin-5-yl)acetate [Clopidogrel base, (I)] and their various pharmaceutically acceptable salts.

Process for preparing clopidogrel

The present invention encompasses processes for the preparation of optically pure clopidogrel camphorsulfonic acid salt without the need to isolate or recover (±) clopidogrel.